Gene signatures and expression of miRNAs associated with efficacy of panitumumab in a head and neck cancer phase II trial

Despite differences in clinical settings and anti-EGFR inhibitors used for treatment, response prediction by the Cluster3 signature and selected miRNAs was essentially the same. Translation into a useful clinical assay requires validation in a broader setting.